Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.4K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

961
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
961
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

241
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
241
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions01:09

Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions

198
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
198
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The combined use of natural language processing and electronic health records data to identify historical tolerances of β-lactams and promote clinician confidence in future use.

Health systems (Basingstoke, England)·2026
Same author

Predicting risk of unplanned subsequent knee surgery following ACL reconstruction.

BMC musculoskeletal disorders·2026
Same author

Assessing Multimodal AI for Visual Information Extraction of Pharmacology.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same author

A Retrospective Pharmacovigilance Disproportionality Analysis of Possible Nephrotoxicity and Natural Products Using Data from the FDA Adverse Event Reporting System.

Journal of integrative and complementary medicine·2026
Same author

Assessment of Growth in Cardio-Facio-Cutaneous Syndrome.

American journal of medical genetics. Part A·2026
Same author

Validity of ICD-10 codes for identifying gastrointestinal bleeding in anticoagulated patients: an encounter-level diagnostic accuracy study.

Journal of thrombosis and thrombolysis·2026

Related Experiment Video

Updated: Aug 17, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management.

Philip D Hansten1, Malinda S Tan2, John R Horn3

  • 1School of Pharmacy, University of Washington, Seattle, WA, USA. hansten@uw.edu.

Drug Safety
|December 15, 2022
PubMed
Summary

Accurate information on colchicine drug-drug interactions (DDIs) is crucial for patient safety. This study evaluates colchicine DDIs, offering evidence-based management to prevent severe adverse outcomes.

More Related Videos

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

1.4K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.0K

Related Experiment Videos

Last Updated: Aug 17, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K
Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
10:33

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

1.4K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.0K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Drug Safety

Background:

  • Colchicine is vital for gout and other conditions.
  • It interacts with CYP3A4 and P-glycoprotein (P-gp), leading to potential severe drug-drug interactions (DDIs).
  • Existing DDI information sources often contain errors and suboptimal management recommendations.

Purpose of the Study:

  • To provide an evidence-based evaluation of drugs that interact with colchicine.
  • To identify drugs erroneously reported to interact with colchicine.
  • To suggest improved management strategies for colchicine DDIs to minimize patient harm.

Main Methods:

  • Review and evidence-based evaluation of reported colchicine drug-drug interactions.
  • Analysis of nearly 100 reported cases of colchicine DDIs.
  • Comparison of existing DDI information with clinical evidence.

Main Results:

  • Many current sources of colchicine DDI information contain inaccuracies.
  • The common recommendation to reduce colchicine dosage with CYP3A4/P-gp inhibitors may lead to toxicity or therapeutic failure.
  • Clinical importance of specific colchicine DDIs varies significantly across sources.

Conclusions:

  • Improved, evidence-based information on colchicine DDIs is necessary.
  • Current management strategies for colchicine DDIs may require revision.
  • Accurate DDI assessment and management are essential to minimize severe adverse outcomes from colchicine therapy.